Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy

Abstract : Aim: Gold nanoparticles have attracted significant interest in cancer diagnosis and treatment. Herein, we evaluated the theranostic potential of dithiolated diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) for CT-contrast enhancement and radiosensitization in prostate cancer. Materials & methods: In vitro assays determined Au@DTDTPA uptake, cytotoxicity, radiosensitizing potential and DNA damage profiles. Human PC3 xenograft tumor models were used to determine CT enhancement and radiation modulating effects in vivo. Results: Cells exposed to nanoparticles and radiation observed significant additional reduction in survival compared with radiation only. Au@DTDTPA produced a CT enhancement of 10% and a significant extension in tumor growth delay from 16.9 days to 38.3 compared with radiation only. Conclusion: This study demonstrates the potential of Au@DTDTPA to enhance CT-image contrast and simultaneously increases the radiosensitivity of prostate tumors.
Complete list of metadatas

Cited literature [42 references]  Display  Hide  Download

https://hal.archives-ouvertes.fr/hal-01405741
Contributor : Béatrice Rayet <>
Submitted on : Monday, December 5, 2016 - 2:58:28 PM
Last modification on : Thursday, November 21, 2019 - 2:39:26 AM

File

hal-01405741.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Karl Butterworth, James Nicol, Mihaela Ghita, Soraia Rosa, Pankaj Chaudhary, et al.. Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy. Nanomedicine, Future Medicine, 2016, 11 (16), pp.2035-2047. ⟨10.2217/nnm-2016-0062⟩. ⟨hal-01405741⟩

Share

Metrics

Record views

233

Files downloads

578